Related Experiment Video

Updated: May 4, 2026

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.0K

Systems mapping of genes controlling chemotherapeutic drug efficiency for cancer stem cells

Weimiao Wu1, Sisi Feng1, Yaqun Wang2

  • 1Center for Computational Biology, Beijing Forestry University, Beijing 100083, China.

Drug Discovery Today
|January 9, 2014
PubMed

Insights

This study introduces a statistical framework to identify genes influencing cancer stem cell drug response. This approach aids in developing personalized cancer therapies by understanding genetic impacts on treatment efficacy.

Area of Science:

  • Oncology
  • Genetics
  • Computational Biology

Background:

  • Chemotherapeutic drugs can control cancer by targeting cancer stem cells.
  • Significant inter-patient variability exists in cancer stem cell drug response.
  • Understanding genetic factors is crucial for effective cancer treatment.

Purpose of the Study:

  • To develop a statistical framework for mapping genes that control tumor response to chemotherapy.
  • To quantify the genetic effects on cancer stem cell kinetics during therapy.
  • To enable personalized medicine by understanding gene-drug interactions.

Main Methods:

  • Integration of the cancer stem cell hypothesis with genetic association studies.
  • Development of a statistical model to quantify genetic effects on cancer stem cell decline.
  • Analysis of gene interactions influencing drug response and treatment efficacy.

Main Results:

  • The framework successfully maps genes controlling tumor response to chemotherapeutic drugs.
  • Quantification of genetic effects on the kinetic decline of cancer stem cells.
  • Identification of specific genes and interactions that govern drug response.

Conclusions:

  • The developed statistical framework provides insights into personalized cancer therapy.
  • Understanding genetic influences on cancer stem cells can improve treatment efficacy.
  • This approach supports the tailoring of chemotherapeutic drugs for individual patients.

More Related Videos

Harnessing the DNA Dye-triggered Side Population Phenotype to Detect and Purify Cancer Stem Cells from Biological Samples09:57

Harnessing the DNA Dye-triggered Side Population Phenotype to Detect and Purify Cancer Stem Cells from Biological Samples

Published on: May 10, 2017

6.9K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.1K

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

2.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.7K